All News #Library
Biotech
Rege Nephro acquires Tamibarotene assets from Syros Pharma.
15 Apr 2025 //
PR NEWSWIRE
Rege Nephro Completes Series B Funding For Kidney Disease Trials
07 Oct 2024 //
PR NEWSWIRE

Market Place
Sourcing Support